Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 757
Filter
1.
Am J Case Rep ; 25: e943915, 2024 Jun 28.
Article in English | MEDLINE | ID: mdl-38941282

ABSTRACT

BACKGROUND Parinaud oculoglandular syndrome is a unilateral granulomatous palpebral conjunctivitis associated with preauricular, submandibular, and cervical lymphadenopathies. Several infectious diseases can cause Parinaud oculoglandular syndrome, usually with a conjunctival entry. The most common underlying pathology is cat scratch disease, followed by the oculoglandular form of tularemia. Diagnosis is usually a serious challenge as these infections are themselves rare. On the other hand, Parinaud oculoglandular syndrome may be a rare manifestation of more common disorders (eg, tuberculosis, syphilis, mumps, herpes simplex and Epstein-Barr virus, adenovirus, Rickettsia, Sporothrix, Chlamydia infections). CASE REPORT We present the case of a 66-year-old man with granulomatous conjunctivitis and ipsilateral preauricular, submandibular, and upper cervical lymphadenopathies following a superficial corneal injury. Although the systematic amoxicillin/clavulanic acid and metronidazole antibiotic therapy started immediately at admission, the suppuration of the lymph nodes required surgical drainage. Based on his anamnesis (sheep breeding; a twig scratching his eye 2 days before the initial attendance) and symptoms, a zoonosis, namely the oculoglandular form of tularemia, was suspected, empiric ciprofloxacin therapy was administered, and the patient recovered without sequelae. The Francisella tularensis infection was eventually confirmed by microagglutination serologic assay. CONCLUSIONS If Parinaud oculoglandular syndrome is diagnosed and cat scratch fever as the most common etiology is not likely, other zoonoses, especially the oculoglandular form of tularemia, should be suspected. Serology is the most common laboratory method of diagnosing tularemia. Empiric fluoroquinolone (ciprofloxacin) or aminoglycoside (gentamicin or streptomycin) antibiotic therapy should be started immediately at the slightest suspicion of oculoglandular tularemia.


Subject(s)
Francisella tularensis , Tularemia , Humans , Male , Tularemia/diagnosis , Tularemia/complications , Tularemia/drug therapy , Aged , Francisella tularensis/isolation & purification , Conjunctivitis, Bacterial/diagnosis , Conjunctivitis, Bacterial/microbiology , Conjunctivitis, Bacterial/drug therapy , Syndrome , Anti-Bacterial Agents/therapeutic use , Ocular Motility Disorders/etiology , Ocular Motility Disorders/diagnosis , Lymphadenopathy/microbiology
2.
Front Cell Infect Microbiol ; 14: 1381776, 2024.
Article in English | MEDLINE | ID: mdl-38628552

ABSTRACT

Introduction: For a majority of tularemia patients, serology is the basis for the diagnosis. The aim of this study was to perform an analysis of the samples analyzed at a Swedish reference laboratory for the presence of Francisella tularensis-specific antibody levels in sera from individuals with suspected tularemia. Annual and monthly variations of the total number of samples and proportions of positive samples were analyzed, as well as the influence of age and gender. Methods: We performed a retrospective analysis of the presence of F. tularensis-specific antibodies in serological samples from patients with suspected tularemia analyzed during the period 2010 - 2022 at the University Hospital of Umeå in Sweden, a national reference laboratory, by use of various statistical methods. In total, some 15,100 serum samples had been analyzed for the presence of IgG and IgM antibodies by ELISA during the 13-year period. Results: Overall, there were higher number of samples with IgG positive or borderline titers, 2,522 and 921, respectively, than with IgM positive or borderline titers, 1,802 and 409, respectively. Repeated samples were obtained from some 1,930 individuals and approximately a third of the cases, which were initially seronegative, had seroconverted when resampled. Peak number of monthly samples were recorded in August and September, > 3,000. Annual numbers varied greatly and peak numbers were observed in 2015 and 2019, 1,832 and 2,250, respectively, whereas some other years the numbers were 700 - 800. There was also much variation in the annual and monthly percentages of positive samples and they varied between less than 10% to greater than 20%. The highest percentages of positive samples were recorded in September and October. IgG and IgM titers declined with age and these differences were highly significant for IgG titers, with decreasing average titers for each 20-year interval. Discussion: Collectively, the data demonstrate the marked annual and seasonal variations in tularemia sampling occurring in Sweden. Also, the proportion of positive samples increased during months and years with peak number of samples. Another notable finding was that average antibody titers decreased with increased age.


Subject(s)
Francisella tularensis , Tularemia , Humans , Tularemia/diagnosis , Tularemia/epidemiology , Sweden/epidemiology , Retrospective Studies , Antibodies, Bacterial , Immunoglobulin M , Immunoglobulin G
3.
Infection ; 52(3): 1165-1169, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38480644

ABSTRACT

In the last 10 years, an increase in tularemia cases has been observed in both humans and animals in Switzerland. In these, infection with Francisella tularensis, the causative agent of the zoonotic disease tularemia, can occur through arthropod vectors or contact to infected animals or exposure to contaminated environmental sources. Currently, we are only able to postulate potential aetiologies: (i) behavioral changes of humans with more exposure to endemic habitats of infected arthropod vectors; (ii) an increased rate of tularemia infected ticks; (iii) increasing number and geographical regions of tick biotopes; (iv) increasing and/or more diverse reservoir populations; (v) increasing presence of bacteria in the environment; (vi) raised awareness and increased testing among physicians; (vii) improved laboratory techniques including molecular testing. To approach these questions, a one-health strategy is necessary. A functioning collaboration between public health, human medicine, and diagnostic and veterinary units for the control of tularemia must be established. Furthermore, the public should be included within citizen-supported-science-projects.


Subject(s)
Francisella tularensis , One Health , Tularemia , Tularemia/epidemiology , Tularemia/transmission , Tularemia/diagnosis , Switzerland/epidemiology , Humans , Animals , Zoonoses/transmission , Zoonoses/epidemiology , Zoonoses/microbiology , Ticks/microbiology , Arthropod Vectors/microbiology
4.
BMJ Case Rep ; 17(3)2024 Mar 29.
Article in English | MEDLINE | ID: mdl-38553022

ABSTRACT

Tularaemia is a highly infectious, zoonotic disease caused by Francisella tularensis, which has become increasingly prevalent over the past decade. Depending on the route of infection, different clinical manifestations can be observed. We report a case of typhoidal tularaemia presenting as a febrile illness with gastrointestinal symptoms in a patient in her mid-80s. During the acute illness phase and in the context of alcohol-related liver cirrhosis, the patient developed progressive ascites. During paracentesis, spontaneous bacterial peritonitis was consistently reported. Blood culture revealed Gram-negative bacilli identified as F. tularensis upon microscopic examination. Immediate clinical improvement was observed after adaptation to a pathogen-specific antibiotic regime. Typhoidal tularaemia presents general, non-specific symptoms without the local manifestations seen in other forms of the disease, thus representing a diagnostic challenge. In the case of protracted fever and if the epidemiological context as well as possible exposure are compatible, tularaemia should be considered in the differential diagnosis.


Subject(s)
Francisella tularensis , Tularemia , Animals , Female , Humans , Tularemia/complications , Tularemia/diagnosis , Tularemia/drug therapy , Ascites/diagnosis , Ascites/etiology , Ascites/drug therapy , Zoonoses/drug therapy , Anti-Bacterial Agents/therapeutic use
5.
Infection ; 52(4): 1607-1614, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38457094

ABSTRACT

BACKGROUND: Tularaemia is a zoonotic disease caused by Francisella tularensis, a highly virulent bacterium that affects humans and small wild animals. It is transmitted through direct contact with infected animals or indirectly through contaminated soil, water or arthropod bites (e.g. ticks). Primary thoracic manifestations of tularaemia are infrequent and, therefore, a diagnostic challenge for clinicians. METHODS: We report six tularaemia cases with exclusively thoracic involvement diagnosed in a clinic for pulmonary diseases in Bavaria between 10/2020 and 02/2022. RESULTS: All patients lived or were active in rural areas, four reported a recent tick bite. All patients presented with thoracic lymphadenopathy and pulmonary tumours or consolidations; all underwent bronchoscopy with EBUS-TBNA of lymph nodes, three lung biopsies as well. Five patients showed inflammatory changes in the endobronchial mucosa. The main histological findings were necrotic epithelioid granulomas with remarkable granulocyte infiltration. All cases were identified by positive serology, five by PCR (here identification of F.t. ssp. Holarctica) from biopsy as well. As first-line therapy, oral ciprofloxacin was given (5/6); in 2/6 cases, a combination of quinolone-rifampicin was given. CONCLUSIONS: Pulmonary tularaemia may occur after tick bites and without extrathoracic manifestations. In patients who present with thoracic lymphadenopathy and pulmonary consolidations and who are exposed to increased outdoor activities, tularaemia should be included in the diagnostic pathway. Histologically, the presence of neutrophil-granulocyte infiltrations might help to distinguish tularaemia from other granulomatous infections, e.g. tuberculosis. The combination of quinolone-rifampicin rather than i.v. gentamicin reduced length of hospital stay in two patients.


Subject(s)
Tularemia , Humans , Tularemia/diagnosis , Tularemia/drug therapy , Tularemia/microbiology , Tularemia/pathology , Male , Middle Aged , Female , Aged , Anti-Bacterial Agents/therapeutic use , Adult , Francisella tularensis/isolation & purification , Lymphadenopathy/microbiology , Lymphadenopathy/pathology , Lymphadenopathy/etiology , Ciprofloxacin/therapeutic use
6.
Clin Infect Dis ; 78(5): 1222-1231, 2024 May 15.
Article in English | MEDLINE | ID: mdl-38393822

ABSTRACT

BACKGROUND: Tularemia is an important reemerging disease with a multimodal transmission pattern. Treatment outcomes of current recommended antibiotic regimens (including ciprofloxacin and doxycycline) remain unclear. In this retrospective cohort study, we report clinical, laboratory, geographical, and treatment outcomes of laboratory-confirmed tularemia cases over an 11-year period in Northern Sweden. METHODS: Data from reported tularemia cases (aged >10 years at time of study) in Norrbotten county between 2011 and 2021 were collected through review of electronic medical records and participant questionnaires; 415 of 784 accepted participation (52.9%). Of these, 327 were laboratory-confirmed cases (serology and/or polymerase chain reaction). A multivariable logistic regression model was used to investigate variables associated with retreatment. RESULTS: Median age of participants was 54 years (interquartile range [IQR], 41.5-65) and 49.2% were female. Although ulceroglandular tularemia was the predominant form (n = 215, 65.7%), there were several cases of pulmonary tularemia (n = 40; 12.2%). Inflammatory markers were largely nonspecific, with monocytosis frequently observed (n = 36/75; 48%). Tularemia was often misdiagnosed on presentation (n = 158, 48.3%), with 65 (19.9%) receiving initial inappropriate antibiotics and 102 (31.2%) retreated. Persistent lymphadenopathy was infrequent (n = 22, 6.7%), with 10 undergoing surgical interventions. In multivariable analysis of variables associated with retreatment, we highlight differences in time until receiving appropriate antibiotics (8 [IQR, 3.25-20.75] vs 7 [IQR, 4-11.25] days; adjusted P = .076), and doxycycline-based treatment regimen (vs ciprofloxacin; adjusted P = .084), although this was not significant after correction for multiple comparisons. CONCLUSIONS: We comprehensively summarize clinical, laboratory, and treatment outcomes of type B tularemia. Targeting tularemia requires clinical awareness, early diagnosis, and timely commencement of treatment for an appropriate duration.


Subject(s)
Anti-Bacterial Agents , Doxycycline , Tularemia , Humans , Tularemia/drug therapy , Tularemia/diagnosis , Tularemia/epidemiology , Sweden/epidemiology , Female , Middle Aged , Retrospective Studies , Anti-Bacterial Agents/therapeutic use , Male , Adult , Aged , Treatment Outcome , Doxycycline/therapeutic use , Francisella tularensis/isolation & purification , Ciprofloxacin/therapeutic use , Young Adult
7.
Prague Med Rep ; 125(1): 79-86, 2024.
Article in English | MEDLINE | ID: mdl-38380456

ABSTRACT

A middle-aged man in his 50s, active smoker, presented to the pulmonary office for lung cancer evaluation. On a low-dose computed tomography for lung cancer screening, he was found to have an 8 mm endobronchial lesion in the right main stem bronchus. A PET-CT revealed no endobronchial lesion, but incidentally, fluorodeoxyglucose (FDG) avidity was present in the right hilar (SUV 13.2) and paratracheal lymph nodes (LNs). He underwent bronchoscopy and EBUS-TBNA of station 7 and 10 R LNs. The fine needle aspiration (FNA) revealed necrotizing epithelioid granuloma. The acid-fast bacilli (AFB) and Grocott methenamine silver (GMS) stains were negative. He had suffered from pneumonic tularemia 13 months ago and immunohistochemical staining for Francisella tularensis on FNA samples at Center for Disease Control and Prevention was negative. The intense positron emission tomography (PET) avidity was attributed to prior tularemic intrathoracic lymphadenitis without active tularemia, a rare occurrence. To the best of our knowledge, PET-positive intrathoracic lymph node beyond one year without evidence of active tularemia has not been previously reported.


Subject(s)
Lung Neoplasms , Tularemia , Male , Middle Aged , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Positron Emission Tomography Computed Tomography/methods , Fluorodeoxyglucose F18 , Early Detection of Cancer , Tularemia/diagnosis , Tularemia/pathology , Lymph Nodes/diagnostic imaging , Lymph Nodes/pathology , Endoscopic Ultrasound-Guided Fine Needle Aspiration/methods , Neoplasm Staging , Retrospective Studies
8.
Infection ; 52(3): 1181-1184, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38206513

ABSTRACT

Treatment of tularemia during pregnancy is challenging due to toxicity of standard treatment regimens. Here, we report a 31-year-old woman with glandular tularemia who was successfully treated with intravenous azithromycin. Follow-up examinations over a 6-month period showed a sustained response to treatment. She later gave birth to a healthy child.


Subject(s)
Anti-Bacterial Agents , Azithromycin , Pregnancy Complications, Infectious , Tularemia , Humans , Female , Tularemia/drug therapy , Tularemia/diagnosis , Azithromycin/therapeutic use , Pregnancy , Adult , Anti-Bacterial Agents/therapeutic use , Pregnancy Complications, Infectious/drug therapy , Pregnancy Complications, Infectious/microbiology , Austria , Treatment Outcome , Francisella tularensis/drug effects , Francisella tularensis/isolation & purification
9.
Clin Infect Dis ; 78(Suppl 1): S15-S28, 2024 01 31.
Article in English | MEDLINE | ID: mdl-38294108

ABSTRACT

BACKGROUND: Francisella tularensis, the causative agent of tularemia, is endemic throughout the Northern Hemisphere and requires as few as 10 organisms to cause disease, making this potential bioterrorism agent one of the most infectious bacterial pathogens known. Aminoglycosides, tetracyclines, and, more recently, fluoroquinolones are used for treatment of tularemia; however, data on the relative effectiveness of these and other antimicrobial classes are limited. METHODS: Nine databases, including Medline, Global Health, and Embase, were systematically searched for articles containing terms related to tularemia. Articles with case-level data on tularemia diagnosis, antimicrobial treatment, and patient outcome were included. Patient demographics, clinical findings, antimicrobial administration, and outcome (eg, intubation, fatality) were abstracted using a standardized form. RESULTS: Of the 8878 publications identified and screened, 410 articles describing 870 cases from 1993 to 2023 met inclusion criteria. Cases were reported from 35 countries; more than half were from the United States, Turkey, or Spain. The most common clinical forms were ulceroglandular, oropharyngeal, glandular, and pneumonic disease. Among patients treated with aminoglycosides (n = 452 [52%]), fluoroquinolones (n = 339 [39%]), or tetracyclines (n = 419 [48%]), the fatality rate was 0.7%, 0.9%, and 1.2%, respectively. Patients with pneumonic disease who received ciprofloxacin had no fatalities and the lowest rates of thoracentesis/pleural effusion drainage and intubation compared to those who received aminoglycosides and tetracyclines. CONCLUSIONS: Aminoglycosides, fluoroquinolones, and tetracyclines are effective antimicrobials for treatment of tularemia, regardless of clinical manifestation. For pneumonic disease specifically, ciprofloxacin may have slight advantages compared to other antimicrobials.


Subject(s)
Francisella tularensis , Tularemia , Humans , Tularemia/diagnosis , Tularemia/drug therapy , Tularemia/epidemiology , Anti-Bacterial Agents/therapeutic use , Ciprofloxacin/therapeutic use , Aminoglycosides/therapeutic use , Tetracyclines/therapeutic use
10.
Clin Infect Dis ; 78(Suppl 1): S47-S54, 2024 01 31.
Article in English | MEDLINE | ID: mdl-38294114

ABSTRACT

BACKGROUND: Tularemia is caused by the gram-negative bacterium Francisella tularensis. Although rare, tularemia during pregnancy has been associated with pregnancy complications; data on efficacy of recommended antimicrobials for treatment are limited. We performed a systematic literature review to characterize clinical manifestations of tularemia during pregnancy and examine maternal, fetal, and neonatal outcomes with and without antimicrobial treatment. METHODS: We searched 9 databases, including Medline, Embase, Global Health, and PubMed Central, using terms related to tularemia and pregnancy. Articles reporting cases of tularemia with ≥1 maternal or fetal outcome were included. RESULTS: Of 5891 articles identified, 30 articles describing 52 cases of tularemia in pregnant patients met inclusion criteria. Cases were reported from 9 countries, and oropharyngeal and ulceroglandular tularemia were the most common presenting forms. A plurality (46%) of infections occurred in the second trimester. Six complications were observed: lymph node aspiration, lymph node excision, maternal bleeding, spontaneous abortion, intrauterine fetal demise, and preterm birth. No deaths among mothers were reported. Of 28 patients who received antimicrobial treatment, 1 pregnancy loss and 1 fetal death were reported. Among 24 untreated patients, 1 pregnancy loss and 3 fetal deaths were reported, including one where F. tularensis was detected in placental and fetal tissues. CONCLUSIONS: Pregnancy loss and other complications have been reported among cases of tularemia during pregnancy. However, risk of adverse outcomes may be lower when antimicrobials known to be effective are used. Without treatment, transplacental transmission appears possible. These data underscore the importance of prompt recognition and treatment of tularemia during pregnancy.


Subject(s)
Abortion, Spontaneous , Anti-Infective Agents , Francisella tularensis , Premature Birth , Tularemia , Humans , Female , Infant, Newborn , Pregnancy , Tularemia/complications , Tularemia/diagnosis , Tularemia/drug therapy , Placenta , Anti-Infective Agents/therapeutic use
11.
Clin Infect Dis ; 78(Suppl 1): S67-S70, 2024 01 31.
Article in English | MEDLINE | ID: mdl-38294110

ABSTRACT

Tularemia is caused by the highly infectious bacterium Francisella tularensis, which is recognized as a Tier 1 bioterrorism agent. Tularemia has a range of recognized clinical manifestations, but fewer than 20 bone or joint infections from 6 countries have been reported in the literature to date. This series includes 13 cases of F. tularensis septic arthritis or osteomyelitis in the United States during 2004-2023 and describes exposures, clinical presentation, diagnosis, and outcomes for this rare but severe form of tularemia. Clinicians should consider F. tularensis in patients with compatible exposures or a history of joint replacement or immunosuppression.


Subject(s)
Arthritis, Infectious , Francisella tularensis , Tularemia , Humans , United States/epidemiology , Tularemia/diagnosis , Tularemia/epidemiology , Tularemia/microbiology , Arthritis, Infectious/diagnosis , Arthritis, Infectious/epidemiology
12.
Clin Infect Dis ; 78(Suppl 1): S55-S63, 2024 01 31.
Article in English | MEDLINE | ID: mdl-38294117

ABSTRACT

BACKGROUND: Neuroinvasive infection with Francisella tularensis, the causative agent of tularemia, is rare. Establishing clinical suspicion is challenging if risk factors or clinical features classically associated with tularemia are absent. Tularemia is treatable with antibiotics; however, there are limited data to inform management of potentially fatal neuroinvasive infection. METHODS: We collected epidemiologic and clinical data on 2 recent US cases of neuroinvasive F. tularensis infection, and performed a literature review of cases of neuroinvasive F. tularensis infection published after 1950. RESULTS: One patient presented with focal neurologic deficits and brain lesions; broad-range molecular testing on resected brain tissue detected F. tularensis. The other patient presented with meningeal signs; tularemia was suspected based on animal exposure, and F. tularensis grew in cerebrospinal fluid (CSF) culture. Both patients received combination antibiotic therapy and recovered from infection. Among 16 published cases, tularemia was clinically suspected in 4 cases. CSF often displayed lymphocytic pleocytosis. Among cases with available data, CSF culture was positive in 13 of 16 cases, and F. tularensis antibodies were detected in 11 of 11 cases. Treatment typically included an aminoglycoside combined with either a tetracycline or a fluoroquinolone. Outcomes were generally favorable. CONCLUSIONS: Clinicians should consider neuroinvasive F. tularensis infection in patients with meningitis and signs suggestive of tularemia or compatible exposures, lymphocyte-predominant CSF, unrevealing standard microbiologic workup, or lack of response to empiric bacterial meningitis treatment. Molecular testing, culture, and serologic testing can reveal the diagnosis. Favorable outcomes can be achieved with directed antibiotic treatment.


Subject(s)
Francisella tularensis , Meningitis , Tularemia , Animals , Humans , Tularemia/diagnosis , Tularemia/drug therapy , Tularemia/microbiology , Anti-Bacterial Agents/therapeutic use , Aminoglycosides/therapeutic use
13.
Clin Infect Dis ; 78(Suppl 1): S64-S66, 2024 01 31.
Article in English | MEDLINE | ID: mdl-38294112

ABSTRACT

A male patient with distant history of extensive rabbit contact and pulmonary nodules for 6 years developed empyema. Francisella tularensis holarctica was isolated from thoracentesis fluid. Retrospective immunohistochemical examination of a pulmonary nodule, biopsied 3 years prior, was immunoreactive for F. tularensis. These findings suggest the potential for chronic tularemia.


Subject(s)
Francisella tularensis , Multiple Pulmonary Nodules , Tularemia , Animals , Humans , Male , Rabbits , Tularemia/diagnosis , Nebraska , Retrospective Studies
15.
Pneumologie ; 78(3): 199-203, 2024 Mar.
Article in German | MEDLINE | ID: mdl-37857320

ABSTRACT

Tularemia is a rare zoonotic disease, endemic in rural areas all over Germany. It's clinical manifestation following inhalation of infectious aerosols may resemble pulmonary neoplasia, other atypical pneumonias or tuberculosis. Here we describe two representative cases with pulmonary tularemia.


Subject(s)
Carcinoma , Lung Diseases, Interstitial , Pneumonia , Tuberculosis , Tularemia , Humans , Tularemia/complications , Tularemia/diagnosis , Tularemia/drug therapy
16.
Vet Q ; 43(1): 1-16, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37916743

ABSTRACT

Tularemia caused by Gram-negative, coccobacillus bacterium, Francisella tularensis, is a highly infectious zoonotic disease. Human cases have been reported mainly from the United States, Nordic countries like Sweden and Finland, and some European and Asian countries. Naturally, the disease occurs in several vertebrates, particularly lagomorphs. Type A (subspecies tularensis) is more virulent and causes disease mainly in North America; type B (subspecies holarctica) is widespread, while subspecies mediasiatica is present in central Asia. F. tularensis is a possible bioweapon due to its lethality, low infectious dosage, and aerosol transmission. Small mammals like rabbits, hares, and muskrats are primary sources of human infections, but true reservoir of F. tularensis is unknown. Vector-borne tularemia primarily involves ticks and mosquitoes. The bacterial subspecies involved and mode of transmission determine the clinical picture. Early signs are flu-like illnesses that may evolve into different clinical forms of tularemia that may or may not include lymphadenopathy. Ulcero-glandular and glandular forms are acquired by arthropod bite or handling of infected animals, oculo-glandular form as a result of conjunctival infection, and oro-pharyngeal form by intake of contaminated food or water. Pulmonary form appears after inhalation of bacteria. Typhoidal form may occur after infection via different routes. Human-to-human transmission has not been known. Diagnosis can be achieved by serology, bacterial culture, and molecular methods. Treatment for tularemia typically entails use of quinolones, tetracyclines, or aminoglycosides. Preventive measures are necessary to avoid infection although difficult to implement. Research is underway for the development of effective live attenuated and subunit vaccines.


Subject(s)
Francisella tularensis , Tularemia , Humans , Animals , Rabbits , Tularemia/diagnosis , Tularemia/epidemiology , Tularemia/veterinary , Zoonoses/microbiology , Anti-Bacterial Agents , Mammals
17.
Ann Clin Microbiol Antimicrob ; 22(1): 92, 2023 Oct 24.
Article in English | MEDLINE | ID: mdl-37875923

ABSTRACT

Francisella tularensis is a Gram-negative bacteria, that may cause a zoonotic disease, tularemia. Here, we describe a patient case, where a previously healthy young woman in Northern Finland contacted health care because of fever and headache. Due to the symptoms and lack of further diagnostic tools in primary health care, she was transferred to University Hospital (UH) where ampicillin and ceftriaxone was given empirically. A cerebrospinal fluid sample (CSF) was drawn showing small Gram-negative rods that grew on chocolate agar after 2 days of incubation. Matrix-assisted laser-desorption-ionization time of-flight (Maldi-tof) did not provide identification, but the bacteria was interpreted as sensitive to ciprofloxacin and the treatment was changed to ciprofloxacin. During the time the patient was infected, there were several positive tularemia samples found in the area. Therefore, an in house tularemia nucleic acid method (PCR) was used on the bacterial culture. Additionally, 16S rDNA sequencing was performed and these methods identified the bacteria as F. tularensis. Fortunately, the patient recovered completely with ciprofloxacin and was discharged without any complications. Our case underlines the need to understand the limits of specific diagnostic methods, such as Maldi-tof, used in clinical laboratory settings. It also highlights the need of both clinicians and laboratory staff to be aware of the many clinical presentations of tularemia when working in an endemic area.


Subject(s)
Francisella tularensis , Meningitis , Tularemia , Female , Humans , Ciprofloxacin/pharmacology , Francisella tularensis/genetics , Polymerase Chain Reaction , Tularemia/diagnosis , Tularemia/drug therapy , Tularemia/microbiology
18.
Emerg Infect Dis ; 29(11): 2349-2352, 2023 11.
Article in English | MEDLINE | ID: mdl-37877608

ABSTRACT

Tularemia is increasing in Austria. We report Francisella tularensis subspecies holarctica isolated from 3 patients who had been bitten by arthropods. Next-generation sequencing showed substantial isolate similarity. Clinicians should consider bloodstream F. tularensis infections for patients with signs/symptoms of ulceroglandular tularemia, and surveillance of potential vectors should be intensified.


Subject(s)
Bites and Stings , Francisella tularensis , Tularemia , Humans , Tularemia/diagnosis , Tularemia/epidemiology , Francisella tularensis/genetics , Austria/epidemiology
19.
Emerg Infect Dis ; 29(10): 2105-2107, 2023 10.
Article in English | MEDLINE | ID: mdl-37735772

ABSTRACT

A previously healthy man in Austria had tularemia epididymo-orchitis develop, leading to unilateral orchiectomy. Francisella tularensis subspecies holartica was detected by 16S rRNA gene sequencing analysis of inflamed granulomatous testicular tissue. Clinicians should suspect F. tularensis as a rare etiologic microorganism in epididymo-orchitis patients with relevant risk factors.


Subject(s)
Francisella tularensis , Orchitis , Tularemia , Male , Humans , Austria/epidemiology , Francisella tularensis/genetics , RNA, Ribosomal, 16S/genetics , Tularemia/diagnosis , Tularemia/epidemiology
20.
Dermatol Online J ; 29(3)2023 Jun 15.
Article in English | MEDLINE | ID: mdl-37591266

ABSTRACT

Tularemia has many atypical presentations which can represent a diagnostic challenge. The history is essential in the investigation of this disease. Bite-induced primary skin lesions should be distinguished from the infrequent immune-mediated secondary skin lesions. Herein, we present an atypical pseudovesicular rash secondary to Francisella tularensis.


Subject(s)
Arthritis, Rheumatoid , Tularemia , Humans , Tularemia/complications , Tularemia/diagnosis , Tularemia/drug therapy , Methotrexate/therapeutic use , Patients , Lymph Nodes , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL